Pacer Advisors, Inc. Immunovant, Inc. Transaction History

Pacer Advisors, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$25.1 - $31.61 $13,629 - $17,164	-543 Reduced 40.43%	800 $21,000
Q1 2024 May 10, 2024	BUY	$30.27 - $43.79 $40,652 - $58,809	1,343 New	1,343 $43,000
Q2 2021 Jul 21, 2021	SELL	$9.4 - $16.85 $43,183 - $77,408	-4,594 Closed	0 $0
Q1 2021 Apr 05, 2021	BUY	$13.08 - $49.6 $28,566 - $108,326	2,184 Added 90.62%	4,594 $74,000
Q4 2020 Jan 20, 2021	BUY	$36.36 - $52.71 $87,627 - $127,031	2,410 New	2,410 $111,000

211

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Pacer Advisors, Inc. with notifications on news.